Reldesemtiv

Summary

Reldesemtiv (CHEMBL4297600) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 6
• Chemistry: 384.4 Da · C19H18F2N6O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297600
Name	Reldesemtiv
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	67454400
Molecular formula	C19H18F2N6O
Molecular weight	384.4
InChIKey	MQXWPWOCXGARRK-UHFFFAOYSA-N

SMILES: C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F

IUPAC name: 1-[2-[[3-fluoro-1-(3-fluoro-2-pyridinyl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide

Also known as: Ck-2127107, CK-2127107, Reldesemtiv, RELDESEMTIV

Patent coverage: 69 distinct patent families (203 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 170 (84%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
spinal muscular atrophy	2	MONDO:0001516	MONDO:0019079

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04944784	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT05442775	PHASE3	TERMINATED	A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
NCT02644668	PHASE2	COMPLETED	A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
NCT02662582	PHASE2	COMPLETED	A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
NCT03160898	PHASE2	COMPLETED	A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03065959	PHASE1	TERMINATED	A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).